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ABSTRACT The lung clearance index (LCI) has strong intra-test repeatability; however, the inter-test
reproducibility of the LCI is poorly defined.
The aim of the present study was to define a physiologically meaningful change in LCI in
preschool children, which discriminates changes associated with disease progression from biological
variability.
Repeated LCI measurements from a longitudinal cohort study of children with cystic fibrosis and
age-matched controls were collected to define the inter-visit reproducibility of the LCI. Absolute change,
the coefficient of variation, Bland–Altman limits of agreement, the coefficient of repeatability, intra-class
correlation coefficient, and percentage changes were calculated.
LCI measurements (n=505) from 71 healthy and 77 cystic fibrosis participants (aged 2.6–6 years)
were analysed. LCI variability was proportional to its magnitude, such that reproducibility defined by
absolute changes is biased. A physiologically relevant change for quarterly LCI measurements in
health was defined as exceeding ±15%. In clinically stable cystic fibrosis participants, the threshold
was higher (±25%); however, for measurements made 24 h apart, the threshold was similar to that
observed in health (±17%).
A percentage change in LCI greater than ±15% in preschool children can be considered physiologically
relevant and greater than the biological variability of the test.
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Introduction
The lung clearance index (LCI), measured by multiple breath washout (MBW), may be a useful
physiological test to clinically monitor lung function in patients with cystic fibrosis. The LCI identifies
early obstructive lung disease [1] and is feasible to perform in young children [2, 3]. In addition, the LCI
has good intra-test repeatability [4–6]; however, there are limited longitudinal data describing inter-test
reproducibility.
Investigators report differing findings for the inter-test reproducibility of the LCI due to variability in
protocol designs, study population and MBW methodology [5–14]. Most notably, time intervals between
repeated tests range from hours to years, and none report reproducibility for time intervals typically used
to clinically track patients with cystic fibrosis (e.g. quarterly) [6, 11, 15]. Comparison between studies
is further limited by the various methodologies that define reproducibility; coefficient of variation (%CV)
[5, 7, 8], the intra-class correlation coefficient (ICC) [6], the limits of agreement from Bland–Altman plots
[5, 9–11] or the coefficient of reproducibility [12, 13]. Reproducibility has most commonly been reported
as Bland–Altman limits of agreement or coefficient of repeatability. Both of these methods assume that the
measurement variability is independent of its magnitude, and analyses have only been tested in health or
for a narrow range of LCI values in participants with cystic fibrosis [12, 15]. If this assumption is not
valid across the spectrum of values observed in clinical practice, the use of the limits of agreement or
coefficient of repeatability may introduce bias in the interpretation of clinically relevant between-visit
changes in the LCI.
An additional challenge of defining outcome reproducibility is only using data from healthy individuals.
This approach accounts for biological variability of the test in a healthy population, but may be too
sensitive in disease as it assumes that any variability observed outside this range is driven by disease
progression. In constrast, defining stability and assuring that observed changes between measurements in
disease are not attributed to natural progression proves difficult; thereby, biological variability based on
disease groups may be too conservative.
In this study, we aim to use longitudinal LCI data collected at multiple time intervals (e.g. 1 month,
3 months, 6 month, 9 months and 12 months) to define inter-visit reproducibility in health and stable
cystic fibrosis. Furthermore, we aim to define reproducibility for repeated measurements made within 24 h
to elucidate if variability in LCI is driven by the biological variability of the test, as changes observed
within this time period are unlikely to be associated with changes in the disease state.
Methods
Study population
Data were collected as part of a prospective multi-centre observational study of preschool children (aged
2.5–6 years) with cystic fibrosis and age-matched healthy controls from three North American cystic
fibrosis centres between January 2013 and June 2015 [3]. MBW was measured at enrolment and 1, 3, 6, 9
and 12 months. All participants, both healthy and with cystic fibrosis, were free of respiratory infection for
at least 4 weeks prior to the enrolment. Symptoms (cough) and treatments (oral or intravenous antibiotics)
were recorded for all subsequent tests. Any measurements for which participants had either cough or
pulmonary exacerbation (defined as respiratory symptoms and treatment with antibiotics) were excluded
from these analyses. Thus, these data should reflect clinically stable visits. The study was approved by the
Research Ethics Board at the Hospital for Sick Children (REB # 1000036303), Riley Children’s Hospital
(1401277863), and the Office of Human Research Ethics at University of North Carolina at Chapel Hill
(13-1258). Informed written consent was obtained from the parent/guardian for all participants.
Reproducibility was also defined from the placebo arm of a randomised cross-over interventional trial
(NCT 02276898) that included participants with cystic fibrosis aged ⩾7 years randomised to a single dose
of either hypertonic saline or isotonic saline [14]. MBW was performed at baseline and 24 h later with at
least 1 week washout between treatment arms [14]. The study was approved by the Research Ethics Board
at the Hospital for Sick Children (REB # 1000024909) and informed written consent was obtained from
the parent/guardian for all participants.
MBW outcomes
MBW tests were performed with the Exhalyzer D (EcoMedics AG, Duernten, Switzerland). Adaptions
were made for testing preschool children [3]. Participants were enrolled if they could complete a single
MBW trial, whereas a MBW test was considered successful if there were at least two technically acceptable
trials. The LCI was calculated as the cumulative expired volume (CEV) divided by the functional residual
capacity (FRC) at 1/40 of the starting gas concentration. LCI5 was calculated at 1/20 of the starting gas
concentration. All MBW traces were reviewed for technical quality and appropriate breathing pattern [16].
Full details are previously published [3].
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Spirometry
Spirometry was performed after MBW. Spirometry was performed according to the American Thoracic
Society/European Respiratory Society standards [17]; different devices were used at each of the three sites.
Absolute values of forced expiratory volume in 1 second (FEV1) were standardised for height, age, sex and
ethnicity using the Global Lung Function Initiative reference equations [18]. Mid-expiratory forced
expiratory flow (FEF25–75%) was reported from the effort with the highest sum of FEV1 and forced vital
capacity.
Statistical analysis
Table 1 summarises the methods applied to calculate the inter-visit reproducibility for each pair-wise
comparison of the six LCI measurements. An average reproducibility was calculated with the pooled
pair-wise results of all time points using the mixed-effects model; the residual standard deviation from the
random effects was used with the mean difference to calculate 95% confidence bands (mean differences
±1.96×standard deviation). To account for repeated observations in the same individuals, the mixed-effects
model was specified with subject as the random factor. An exchangeable correlation structure was used.
LCI values were right skewed, therefore non-parametric summaries are presented, whereas percentage
change in LCI followed a normal distribution, and parametric summaries were used. The same analyses
were conducted for FEV1 and FEF25–75% z-scores and % predicted. The sample size was a convenience
sample size based on available data from the primary research study [3]. All statistical analyses were
performed using Stata version 14 (StataCorp, College Station, TX, USA).
Results
77 participants with cystic fibrosis and 71 healthy preschool children had at least two MBW measurements
performed during the study period. Of the 324 technically acceptable MBW measurements in healthy
participants, 295 (91%) were asymptomatic; whereas, of the 343 technically acceptable MBW tests in cystic
fibrosis participants, 210 (61%) were considered asymptomatic and clinically stable. The LCI was
significantly higher in the cystic fibrosis group (median 8.9 (range 6.4–16.2)) at the enrolment visit
compared with the healthy children (median 7.1 (range 6.1–8.1)). The reproducibility, defined as the
absolute difference of LCI between two repeated measurements was close to zero in both health (mean
difference: −0.03) and cystic fibrosis (mean difference: −0.05), regardless of the time interval between
measurements; whereas the within-subject between-test %CV of the LCI was approximately double that in
cystic fibrosis (7.7%) compared with healthy children (4.3%) (table 2). The ICC, representing the
correlation between two measurements in the same individual, was much lower for healthy children
(average 0.4), compared with cystic fibrosis participants (average 0.7).
A meaningful change in LCI can be defined as 0.9 units (table 2) based on the Bland–Altman limits of
agreement (figure 1) and coefficient of repeatability calculated from healthy data. Thus, the probability
that a change of more than 0.9 LCI units is due to chance is less than 5%, and can be considered clinically
meaningful. The threshold is more than double (2 LCI units) when derived from measurements in
TABLE 1 Summary of statistical methods used to calculate the inter-visit reproducibility
Method Calculation Assumptions
Absolute differences LCIt2−LCIt1
Percentage change (LCIt2−LCIt1)×100/LCIt1
Within-subject between-test
standard deviation
Difference of each LCI value from the mean LCI
for each subject
Coefficient of variation [32] Within-subject standard deviation×100/
within-subject mean
Bland and Altman limits of
agreement [36]
Mean difference (LCIt2−LCIt1)±1.96×SD of the
differences
The variance is
proportional to the
mean
Coefficient of
reproducibility [37]
Within-subject standard deviation×2.77 The variance is
proportional to the
mean
Intra-class coefficient [35] Proportion of observed variance between
individuals calculated using a random effects
model
LCI: lung clearance index; t: time or test occasion.
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clinically stable cystic fibrosis participants. However, both the limits of agreement and coefficient of
repeatability assume that the within-subject standard deviation is proportional to the magnitude of the
measurement, which we observed not to be the case (figure 2). The bias was not as apparent for healthy
children in whom the range of LCI values is narrow, but this bias increases in cystic fibrosis, especially at
higher LCI values (figure 2). Thus, using the limits derived in healthy children in cystic fibrosis would
lead to over-estimation of clinically relevant changes in those with higher LCI values (i.e. greater disease
severity).
The reproducibility of repeated LCI measurements for each of the time intervals, calculated as a percentage
change, was, on average, very close to zero in both health and stable cystic fibrosis (table 2) and
independent of the magnitude of LCI (figure 3). To assess the percentage change in LCI that would be
considered a threshold beyond the biological variability of the test, we used the average of the pair-wise
repeated measurements; 95% of the percentage change observed in healthy preschool children was between
±15%. In cystic fibrosis participants, the limits were higher (±25%). The percentage change was similar for
TABLE 2 Reproducibility of lung clearance index between each pair of repeated measurements
in preschool children
Subjects n Absolute
Difference
%CV Limits of
agreement
CR ICC Percentage
change
(95% limits)
Healthy controls
Enrolment–1 month 46 −0.11 4.39 −1.14–0.91 0.85 0.40 −1.4 (−16–13)
Enrolment–3 months 44 −0.18 4.26 −1.18–0.81 0.84 0.48 −2.4 (−16–11)
3–6 months 45 0.24 4.52 −0.87–1.34 0.89 0.52 3.7 (−12–19)
6–9 months 48 −0.19 4.41 −1.33–0.96 0.88 0.44 −2.3 (−17–13)
9–12 months 47 0.01 4.27 −1.10–1.13 0.85 0.59 0.4 (−15–16)
Enrolment–6 months 47 0.07 3.68 −0.88–1.02 0.74 0.49 1.1 (−12–14)
Enrolment–9 months 41 −0.13 4.58 −1.27–1.01 0.90 0.27 −1.7 (−17–14)
Enrolment–12 months 44 −0.07 4.43 −1.32–1.18 0.89 0.36 −0.9 (−18–16)
Average −0.03 4.3% −1.1–1.1 0.90 0.40 −0.14 (−15–15)
Cystic fibrosis
Enrolment–1 months 21 0.36 8.30 −2.94–3.66 2.29 0.70 4.0 (−28–36)
Enrolment–3 months 38 −0.03 6.35 −2.03–1.98 1.54 0.88 0.6 (−22–23)
3–6 months 37 −0.07 7.96 −2.92–2.79 2.03 0.74 1.1 (−27–29)
6–9 months 33 −0.36 7.58 −3.13–2.40 1.98 0.68 −2.4 (−29–24)
9–12 months 35 0.12 5.53 −1.93–2.17 1.42 0.83 2.1 (−19–24)
Enrolment–6 months 35 −0.09 7.39 −2.61–2.43 1.90 0.54 0.6 (−26–27)
Enrolment–9 months 37 −0.08 9.01 −3.12–3.47 2.35 0.58 3.0 (−31–37)
Enrolment–12 months 35 0.10 9.23 −3.54–3.73 2.52 0.74 3.3 (−32–39)
Average −0.05 7.7% −2.9–2.8 2.00 0.70 1.27 (−25–27)
%CV: coeffiecient of variation; CR: coefficient of reproducibility; ICC: intra-class correlation coefficient. The
average was calculated from the pooled pair-wise comparisons of all of the time points as the residual
standard deviation from the random effects of a mixed-effects model.
FIGURE 1 Bland–Altman plot of the
difference in repeated lung
clearance index (LCI)
measurements. The difference
between LCI measurements is
greater at higher LCI values. CF:
cystic fibrosis.
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measurements made 1 month apart compared with those made 3 months apart, in both health and cystic
fibrosis (table 2). In addition, the percentage change in LCI was similar for each of the pair-wise
comparisons across the 12-month period in healthy children and cystic fibrosis participants, albeit the
range was much wider for the cystic fibrosis group (figure 4). LCI5, at 1/20 of the starting concentration,
was more variable than the standard LCI (at 1/40 of the starting gas concentration), with 95% confidence
bands in health ranging from −35% to 34%. The observed percentage change for FEV1 were similar to
those observed for LCI (95% confidence bands in health (−19–16%) and cystic fibrosis (−29–26%));
however, the reproducibility of FEF25–75% were more than double that observed for FEV1 and LCI in both
health and cystic fibrosis (table 3). Since interpretation of % predicted can be biased, we include the
absolute changes in z-scores which were also more variable in cystic fibrosis than in health, and were more
variable for z FEF25–75% than for zFEV1.
LCI reproducibility was also defined for measurements in cystic fibrosis participants made 24 h apart. The
average percentage change was −1.3% (95% confidence bands ±17%). When the limits defined in healthy
preschool children were applied, 16 (94%) out of 17 measurements made 24 h apart in cystic fibrosis
participants had a percentage change in LCI within ±15% of the baseline measurement and 100% within
±25%. In contrast, using an absolute change, only 9 (53%) out of 17 of the 24 h measurements in cystic
fibrosis participants were within 0.9 units in LCI (the coefficient of repeatability derived from the healthy
preschool children).
Discussion
We comprehensively assessed the biological variability of repeated LCI measurements at time points
relevant for clinical care of cystic fibrosis patients. These data highlight that the interpretation of LCI in
terms of absolute change (i.e. 1 unit) is prone to bias, especially in cystic fibrosis. A percentage change in
LCI of ±15% could be considered greater than the biological variability of the test in healthy children, and
is comparable to measurements made 24 h apart in cystic fibrosis. In clinically stable cystic fibrosis
patients measured at longer time intervals (1–3 months), the biological variability was within ±25%. The
greater variability likely represents asymptomatic and spontaneous variations in disease not captured by
FIGURE 2 The within–subject
between-test standard deviation of
the lung clearance index (LCI) was
found to be proportional to the
magnitude, especially in cystic
fibrosis (CF) subjects.
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FIGURE 3 The percentage change
in lung clearance index (LCI)
between two test occasions was
found to be independent of the
magnitude of the LCI.
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clinical symptoms; however, differentiating biological variability from changes in disease state in this
population is challenging and requires further investigation. Our previous work highlighted the
population-level changes in LCI in preschool children over time and identified changes in LCI are
associated with lower respiratory symptoms [3]. The in-depth analyses of the individual-level biological
variability of the LCI presented here provide further evidence and tools to interpret clinical changes in LCI
in young children with cystic fibrosis.
Changes in LCI >15% can be considered physiologically relevant and greater than the biological variability
of the test in health. At the healthy spectrum of LCI (i.e. LCI=7), a 15% change in LCI reflects a change of
approximately 1 unit, which coincides with the Bland–Altman limits of agreement and coefficient of
repeatability defined in this study. The inter-visit %CV and absolute change in LCI are consistent with
previous literature; however the range of observed LCI values in previous studies was narrower, thus the
relationship between the variability and magnitude may not have been apparent [6, 12, 15]. For instance,
SINGER et al. [12] reported a coefficient of repeatability of 0.96 units for measurements in cystic fibrosis
made 24 h apart, which was similar to what we observed in healthy participants. The LCI values observed
by SINGER et al. [12] ranged from 7.3 to 11.5 units in cystic fibrosis; thereby, are not representative of the
spectrum of lung disease observed in patients with cystic fibrosis. In our data, at the severe spectrum of
cystic fibrosis lung disease (i.e. LCI=16), the LCI would need to change by more than 2.5 units to be
considered physiologically relevant, highlighting the limitations of using absolute LCI as a threshold for a
relevant change. We also observed greater variability for the LCI5 between visits than for LCI (at 1/40 the
starting N2 concentration), which is opposite to the within-visit variability [3] but corresponds to the
effects observed for interventional studies [19].
The observed within-subject between-test reproducibility of LCI was relatively high (±15%), but consistent
with FEV1 reproducibility defined using similar methods in the same study population. Absolute z-scores
changes ranged from −1.3 to 1 z-scores, corresponding to approximately −19% to 16% percentage change
when using % predicted. This z-score range is similar to a previous study in children reporting
reproducibility for measurements made 12 months apart [20]. Furthermore, multiple studies demonstrate
that the “signal” such as treatment differences, or changes related to worsening symptoms, from both of
these lung function tests is much greater than the “noise” or biological variability and can be useful for
tracking cystic fibrosis lung disease over time [1, 3, 21–24]. The similar within-subject variability observed
for LCI and FEV1 is in contrast to the lower between-subject variability observed for LCI compared to
FEV1 in interventional studies [7, 8, 25]. This paradox is not unexpected, since changes at a group level
are often lower than changes observed within an individual [26, 27]. Compared with the reproducibility of
the LCI and FEV1, the reproducibility of the FEF25-75% was rather poor (absolute z-score changes ranged
from −2.5 to 1.8 z-scores, which corresponds to approximately −55% to 65% percentage changes when
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FIGURE 4 Percentage changes between LCI measurements were independent of the time interval between
measurements in both health and in stable cystic fibrosis disease. Boxplots indicate the median value (centre
line); inter-quartile range (box) and minimum and maximum values, excluding outliers greater than
three-times the lower quartile (error bars).
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TABLE 3 Reproducibility of FEV1 and FEF25-75% z-scores for absolute change (95% limits of agreement) and % predicted for percentage change (95% confidence
bands)
Subjects n FEV1 z-scores
absolute change
FEV1 % predicted
percentage change
Subjects n FEF25-75% z-scores
absolute change
FEF25-75% % predicted
percentage change
Healthy controls
Enrolment–1 month 31 −0.1 (−1.4–1.1) −1.6 (−20–17) 21 −0.4 (−1.9–1.2) −7.8 (−47–31)
Enrolment–3 months 26 −0.3 (−1.5–0.9) −3.5 (−22–15) 15 −0.1 (−1.2–1) −1.3 (−36–34)
3–6 months 28 −0.1 (−1.3–1.2) 0.4 (−15–16) 17 −0.1 (−1.4–1.1) −2.1 (−34–30)
6–9 months 31 0.03 (−1.3–1.2) −0.6 (−17–16) 21 0.02 (−1.3–1.2) 1.2 (−32–34)
9–12 months 31 0.003 (−1.2–1.2) 0.7 (−18–19) 25 0.1 (−1.3–1.4) 3.7 (−39–46)
Enrolment–6 months 31 −0.2 (−1.6–1.3) −2.0 (−26–22) 15 −0.2 (−1.5–1.0) −4.7 (−38–28)
Enrolment–9 months 28 −0.2 (−1.5–1.0) −2.9 (−25–19) 16 −0.1 (−1.5–1.3) −1.8 (−39–35)
Enrolment–12 months 28 −0.4 (−1.6–0.9) −4.4 (−22–14) 16 −0.5 (−2.6–1.5) −9.8 (−58–38)
Average −0.1 (−1.3–1.0) −1.5 (−19–16) −0.1 (−1.3–1.1) −1.2 (−31–34)
Cystic fibrosis
Enrolment–1 months 16 −0.1 (−1.6–1.4) −1.5 (−26–23) 13 −0.5 (−2.5–1.5) −10.4 (−55–34)
Enrolment–3 months 18 −0.2 (−1.8–1.4) −2.3 (−28–23) 11 −0.4 (−3.3–2.5) −7.0 (−75–61)
3–6 months 19 −0.3 (−2.0–1.3) −3.8 (−27–20) 14 −0.1 (−1.9–1.7) 1.0 (−46–48)
6–9 months 19 0.2 (−1.8–2.2) 3.6 (−33–40) 15 −0.2 (−2.3–1.9) −3.7 (−74–67)
9–12 months 26 0.1 (−1.6–1.8) 2.4 (−25–30) 21 0.2 (−1.5–2.0) 12.1 (−57–81)
Enrolment–6 months 16 −0.4 (−2.2–1.4) −5.3 (−32–22) 13 −0.6 (−3.5–2.3) −8.5 (−77–60)
Enrolment–9 months 19 −0.03 (−1.8–1.8) 0.3 (−28–28) 12 −0.6 (−3.2–1.9) −11.0 (−74–52)
Enrolment–12 months 24 −0.2 (−2.1–1.8) −1.2 (−31–29) 20 −0.6 (−2.7–1.5) −13.2 (−63–36)
Average −0.1 (−1.8–1.6) −1.3 (−29–26) −0.4 (−2.5–1.8) −5.0 (−55–65)
FEV1: forced expiratory volume in 1 s; FEF25–75%: mid-expiratory forced expiratory flow. The average was calculated from the pooled pair-wise comparisons of all of the time points as the
residual standard deviation from the random effects of a mixed-effects model.
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using % predicted). This is consistent with previous literature which suggests both the within- [28] and
between-subject variability [29] of the FEF25-75% is too high to track individuals over time, despite the
sensitivity of FEF25-75% to detect differences at the population level [30].
Numerous statistical approaches exist to calculate the biological variability of a test, each with its own
advantages, disadvantages and statistical assumptions that may be specific to an outcome. Generally, less
variable measurements are more precise, thus better at tracking individuals over time [31]. The Bland–
Altman limits of agreement are widely used to define a threshold of measurement error and biological
variability, but assume that the error is independent of the measurement itself [32]. Our findings clearly
demonstrate that, for LCI, this assumption does not hold true. The effect was less obvious in healthy
participants (Bland–Altman limits of agreement defined in health); therefore, likely to impact the
interpretation of changes observed in cystic fibrosis, where the bias is more pronounced. The discordance
with previous studies is not unexpected since these were either limited to healthy subjects, or a narrow
range of LCI values [12, 15]. In some previous studies within-test repeatability criteria of the FRC and LCI
have been applied, such that higher LCI measurements with greater variability were excluded [6]. MBW
data in our study relied on a standardised quality control protocol that examined trials for technical
quality and variability of the breathing pattern, thus no exclusions were made based on measurement
variability.
Previous studies define inter-test reproducibility as the %CV [5, 7, 8] or the ICC [6]. Both of these are
useful parameters to summarise consistency and agreement, but do not provide a meaningful limit of
reproducibility [33]. Furthermore, both the %CV and ICC are better suited for situations where there are
more than two repeated measurements in the same individual [34] which were not available for most of
the previously published data sets. The %CV observed in our study was comparable to values previously
published [5, 7, 8]; whereas the ICC was much lower. O’NEILL et al. [6] report that the ICC of LCI
measurements made in cystic fibrosis participants approximately 8 months apart (range 67–614 days) was
0.96. The discordance in results likely reflects the inherent sensitivity of the ICC to the magnitude (or
spread) of values in the dataset [33]. Indeed, the ICC calculated from the healthy children in our study
was much lower than the 0.6 limit suggested as a threshold for a meaningful test [35], but the spread of
values in health was smaller. A similar bias can be expected if results in cystic fibrosis participants
represent only a small segment of the spectrum of disease.
Limitations
Our findings are limited by the narrow age range of preschool data, and may not be generalisable to older
patients with more advanced lung disease. These observations were based on patients followed at three
centres and there is a need to validate in a different study populations. Further longitudinal studies in
older cystic fibrosis patients across a range of disease severity are necessary to better interpret changes seen
in the clinical setting. The lack of a gold standard to define the variability of LCI (or FEV1) in cystic
fibrosis limited our ability to distinguish variability due to asymptomatic disease from inherent variability
of ventilation inhomogeneity in those with cystic fibrosis; the 24 h reproducibility data from a small
number of older patients does suggest that biological variability of LCI is similar in health and cystic
fibrosis, and the poorer reproducibility observed at longer time intervals is associated with progression of
lung disease. Additional studies, potentially including images of both structural changes as well as images
of ventilation (e.g. hyper-polarised gas magnetic resonance imaging) may help to better understand LCI
variability observed in cystic fibrosis patients who clinically appear stable. Finally, the spirometry collected
in preschool children was limited to a smaller number of observations, and thus the results may be more
variable than those observed in older children and adults. These were included as a reference and
comparison, and were not meant to define reproducibility of preschool spirometry.
Conclusion
Our findings suggest that the reproducibility of LCI between two consecutive measurements should be
interpreted as percentage changes, where changes greater than ±15% represent changes greater than the
biological variability of the test and are physiologically relevant.
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